NCT01784445View on ClinicalTrials.gov

Post ERCP Pancreatitis Prevention in Average Risk Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

February 28, 2015

Conditions
Pancreatitis
Interventions
DRUG

Ceftazidime

Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure

Trial Locations (1)

51000

Clinical Hospital Centre, Rijeka

All Listed Sponsors
lead

University Hospital Rijeka

OTHER

NCT01784445 - Post ERCP Pancreatitis Prevention in Average Risk Patients | Biotech Hunter | Biotech Hunter